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Abstract
Introduction. Pulmonary alveolar proteinosis is an un-
common disease characterized by the accumulation of sur-
factant proteins and phospholipids within the alveolar
spaces. Acquired disease can be idiopathic (primary) and
secondary. The prevalence of acquired pulmonary alveolar
proteinosis is about 0.37 per 100,000 persons. Common
symptoms are dyspnea and cough. Chest X-ray shows bilat-
eral perihilar infiltrates. Open-lung biopsy is the gold stan-
dard for the diagnosis. Treatment includes whole-lung la-
vage, application of granulocyte-macrophage colony-
stimulating factor and lung transplantation. Case report.
We reported a 51 year-old man with primary form of the
disease. It was the second case of this extremely rare disease
in the past 30 years in our clinic. The symptoms were long-
lasting dry cough, fever and physical deterioration. Chest X-
ray revealed bilateral pulmonary infiltrates; computed to-
mography showed patchy ground-glass opacification with
interlobular thickening. The diagnosis was established by
open lung biopsy. Additional tests were performed to ex-
clude secondary form of the disease. Conclusion. We pre-
sented a rare clinical entity with typical clinical features and
clinical and radiological course of the disease, in order to
improve differential diagnostic approach to patients with
bilateral lung infiltrations. In patients with pulmonary al-
veolar proteinosis timely diagnosis and adequate treatment
can improve a prognosis.
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Apstrakt
Uvod. Pluýna alveolarna proteinoza je retka bolest koja se ka-
rakteriše akumulacijom proteina surfaktanta i fosfolipida u al-
veolarnim prostorima. Steÿena forma bolesti može biti idio-
patska (primarna) i sekundarna. Uÿestalost primarnog oblika
bolesti je oko 0,37 na 100 000 osoba. Simptomi bolesti su
otežano disanje i kašalj. Radiografija pluýa pokazuje bilateral-
ne perihilarne infiltrate. Otvorena biopsija pluýa je zlatni sta-
ndard za postavljanje dijagnoze. U leÿenju se primenjuju po-
navljane bronhioalveolarne lavaže ÿitavih pluýa, primena fa-
ktora stimulacije kolonija granulocita i makrofaga i transplan-
tacija pluýa.  Prikaz bolesnika. Prikazali smo 51-godišnjeg
bolesnika sa primarnim oblikom bolesti. Radi se o drugom
sluÿaju ove izuzetno retke bolesti u prethodnih 30 godina u
našoj klinici. Bolest se prezentovala dugotrajnim suvim kaš-
ljem, povišenom telesnom temperaturom i telesnim propada-
njem. Radiografski, viĀeni su obostrani pluýni infiltrati, a
kompjuterizovana tomografija pokazala je mestimiÿne infitra-
cije izgleda mleÿnog stakla sa interlobularnim zadebljanjima.
Dijagnoza je postavljena otvorenom biopsijom pluýa. Uÿinje-
na su i dodatna ispitivanja kako bismo iskljuÿili sekundarnu
formu bolesti. Zakljuÿak. Prikazan je redak kliniÿki entitet sa
tipiÿnom kliniÿkom slikom, kliniÿkim i radiološkim tokom
bolesti da se poboljša diferencijalno dijagnostiÿki pristup bo-
lesnicima sa obostranim promenama u pluýima. Kod bolesni-
ka sa pluýnom alveolarnom proteinozom pravovremena dija-
gnoza i adekvatno leÿenje mogu popraviti prognozu.
Kljuÿne reÿi:
pluýa, alveolna proteinoza; dijagnoza, diferencijalna;
radiografija; tomografija, kompjuterizovana,
rendgenska; biopsija.
Introduction
Pulmonary alveolar proteinosis (PAP) is an uncommon
disease characterized by the accumulation of surfactant pro-
teins and phospholipids within the alveolar spaces 
1.
Acquired PAP can be idiopathic (primary) PAP and
secondary PAP. Secondary PAP is associated with hemato-
logical malignancies, Pneumocystis carinii pneumonia and
inhalation of silica or titanium 
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The prevalence of acquired pulmonary alveolar protei-
nosis has been estimated to be 0.37 per 100,000 persons 
4. It
is a primary acquired disorder in more than 90 percent of ca-
ses 
4, 5. It is thought that impairment of surfactant clearance
by alveolar macrophages, by autoantibody inhibition of the
action of granulocyte-macrophage colony-stimulating factor
(GM-CSF) may underlie many acquired cases, whereas con-
genital disease is most commonly attributable to mutations in
surfactant protein genes, but may also be caused by GM-CSF
receptor defects 
2, 3.
Symptoms are persistent dry cough, progressive
dyspnea, fatigue and malaise, weight loss, intermittent low-
grade fever and/or night sweats and pleuritic chest pain.
Signs are usually non-specific and include: fine end-
inspiratory crackles, digital clubbing and  cyanosis 
2, 4.
In acquired pulmonary alveolar proteinosis, routine
blood counts and the results of routine blood chemical
analysis and urine analysis are usually normal 
5, 6.
Pulmonary function tests (PFTs) can be normal, but
typically there are restrictive ventilatory defect with slight
impairments in the forced vital capacity and total lung
capacity and a disproportionate, severe reduction of the car-
bon monoxide diffusing capacity 
7. Hypoxemia is caused by
ventilation–perfusion inequality and intrapulmonary shun-
ting, resulting in a widened alveolar–arteriolar diffusion gra-
dient 
5, 8.
Chest X-ray (CXR) shows bilateral perihilar consoli-
dation. Changes progress into a diffuse reticular pattern 
1.
High-resolution computed tomography scan of the chest
shows patchy ground-glass opacification with interlobular
thickening. Similar appearance can be seen in lipoid pne-
umonia, sarcoidosis and acute respiratory distress
syndrome 
3.
In most cases, the diagnosis is confirmed by bronchoal-
veolar lavage (BAL) and transbronchial biopsy.
Macroscopically, BAL fluid shows milky appearance and
microscopically characteristic acellular globules. Histopat-
hological finding of lung biopsy shows periodic acid schift
(PAS)-positive material within the alveoli but contains no
organisms or any excessive cellular response 
3, 7. Surgical
lung biopsy is rarely necessary 
5, 8.
Treatment includes whole-lung lavage which often pro-
duces a dramatic response 
9. Subcutaneous application GM-
CSF and lung transplantation are the therapeutic options
too, 
5.
Case report
A 51-year-old male was admitted to the Clinic for Lung
Diseases due to fever and radiological changes in the lungs
bilaterally (Figure 1). Symptoms were as follows fever (up to
37,8
oC), dry cough, weakness, fatigue, physical decline las-
ted for several months. The patient denied any possible
exposure to occupational hazards or toxic fumes. He had no
risk factors for human immunodeficiency virus (HIV) or ot-
her infections. He denied any previous medical illnesses and
was not taking any medications. He was a smoker for 30
years, smoking 40 cigarettes per day.
Fig. 1 – Frontal chest radiography reveals bilateral air-space
opacity without evidence of pleural effusion or mediastinal
widening. A faintly reticular pattern is present, representing
thickened, interlobular septa
On two occasions, he was examined and treated in the
hospital, with different antibiotic therapy and low doses of
corticosteroids with minimal improvement: he became afeb-
rile, but symptoms and radiographic changes continued to
progress.
Physical examination showed a dysphonic patient with
mild peripheral cyanosis. Auscultation of the lungs revealed
weakened respiratory sound, prolonged expirium bilaterally
and diffuse fine end-inspiratory crackles. Other physical
examination findings were within normal limits.
Initial laboratory tests revealed erythrocyte sedimenta-
tion rate of 40 mm/h and normal complete blood count. Pa-
rameters of blood biochemistry, transaminases and tumor
markers were in normal ranges except lactate dehidro genase
(LDH) 484 IU/L (normal range 200–378 IU/L).
Virus analyses such as hepatitis B surface antigen
(HbsAg), hepatitis C virus (HCV) and HIV antibodies were
negative. Sputum and blood cultures were bacteriologically
and cytologically negative.
PFTs showed a severe restrictive ventilatory changes
(forced vital capacity was 35 percent predicted). The
respiratory arterial blood gases analysis at rest showed severe
hypoxemia with pO2 6,4 KPa (9.1 is normal for his age),
oxygen saturation at 86% (normal > 94 %) and mild
hypocapnia with pCO2 4.5 KPa (normal range 4,6–6).
Multislice computed tomography scan of the chest re-
vealed patchy ground-glass opacification with interlobular
thickening bilaterally, without fibrotic changes (Figure 2).
Bronchoscopic finding was normal. Histological findings of
transbronchial biopsy specimen were nonspecific. The
examination of bronchial aspirates did not reveal any biolo-
gical agents. CXR changes continued to progress. The open-
lung biopsy was performed because there was no diagnosis.
Five days after the intervention, tachypnea, tachycardia and
cyanosis occurred with severe impairment of consciousness
and a progression of radiographic changes (Figure 3).Volumen 69, Broj 11 VOJNOSANITETSKI PREGLED Strana 1007
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Fig. 2 –  Multislice computed tomography scan of the chest
reveals patchy ground-glass opacification with interlobular
thickening bilaterally, without fibrotic changes
Fig. 3 – The fourth postoperative day: progression of
radiographic changes
The arterial blood gases were as follows pO = 6.0 KPa,
pCO = 2 4.4 KPa; sO2 = 82%.
Additional tests were performed for suspected
pulmonary thromboembolism. Electrocardiography showed
sinus tachycardia, with the frequency of 150/min and incom-
plete right bundle branch block. D-dimmer (fibrin degradati-
on fragment) was 747 ng/mL  (normal < 500 ng/mL).
Echocardiography revealed normal left ventricle systolic and
diastolic function, mild elevation of right ventricle systolic
pressure (5 KPa) with normal  dimensions of heart cavities.
The patient developed respiratory failure. Mechanical
ventilation was applied, but despite the intensive treatment
there was a fatal outcome on the same day.
Immediate cause of the patient's death was not determi-
ned because the autopsy was not performed.
Histopathological findings from an open lung biopsy,
arriving three days after the patient's death, showed PAP (Fi-
gures 4, 5 and 6).
Fig. 4 – Alveoli are filled with eosinophilic lipoproteinaceous
material with otherwise relatively preserved lung
architecture; clefts of cholesterol crystals are marked
(HE, u5)
Fig. 5 – Diffuse immunohistochemical reaction in
the alveolar content (Surfactant A, u5)
Fig. 6 – Alveoli are filled with granular material (PAS, u40)
Discussion
Primary PAP is a rare syndrome that was first described
by Rosen et al. in 1958 
4. This disorder is characterized by
abnormal intra-alveolar surfactant accumulation with a vari-
able clinical course, ranging from respiratory failure to
spontaneous resolution 
6. Three distinct clinical forms of
PAP can be distinguished: congenital, secondary, and
primary (idiopathic) 
4.
This rare lung disorder generally occurs in persons of
30 to 50 years of age 
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nosis is 39 years 
4. Most patients are men, and 72% have a
history of smoking 
5.
Congenital PAP is a heterogeneous group of disorders ca-
used by mutations in surfactant proteins B or C, or the receptor
for GM-CSF 
2, 3, 4. Secondary PAP can develop in association
with various conditions, such as immunodeficiency states,
acute silicosis and other inhalational syndromes, hematologic
malignancies and myelodysplastic syndromes 
5, 6. In all of these
conditions there is a reduction in the number and/or functional
impairment of alveolar macrophages 
6, 10. More than 90% of all
cases of PAP occur as the primary (idiopathic) form 
5. Recent
studies have led to the current concept that primary PAP is an
autoimmune disease, which produces neutralizing immunoglo-
bulin G (IgG) antibodies against GM-CSF 
11. Surfactant is
normally cleared by uptake into alveolar macrophages and
GM-CSF is critical for this process, as it is a cytokine stimula-
ting the production of alveolar macrophages by the bone
marrow. Therefore, all the three forms of PAP share the feature
of an impairment in the number and/or activity of alveolar mac-
rophages leading to the alveolar accumulation of surfactant 
1, 3.
The major complication of PAP is an infection with unu-
sual organisms such as Aspergillus species, Nocardia species,
Mycobacterium species, Cryptococcus neoformans, Histopla-
sma capsulatum, Pneumocystis carinii, and viruses 
9.
The serum level of LDH is frequently elevated, but this
finding is non-specific 
5. It may be a useful marker of the
severity of the disease 
3. Elevations in the serum levels of
carcinoembryonic antigen, cytokeratin 19, mucin KL-6, and
surfactant proteins A, B, and D are described but with limi-
ted significance 
6.
Open-lung biopsy is the gold standard for the diagnosis
and reveals alveoli filled with granular, eosinophilic material
that is stained with PAS with preservation of the alveolar ar-
chitecture 
3, 4. This procedure is not always required and can
be complicated by false negative results due to sampling er-
ror 
4. Transbronchial biopsy can generally provide a suffici-
ent tissue sample 
7.
In one third of the patients, no appreciable disability
develops and the disease remits spontaneously or fails to
progress. The natural history depends on the underlying
etiology. Estimates of a 5-year mortality rates vary between
10% and 30% 
9.
Successful lung transplantation has been reported in cases
of congenital PAP 
6. The whole-lung lavage remains the sta-
ndard of care for primary PAP, although some patients may re-
spond to subcutaneous application of GM-CSF11. In secondary
PAP, the treatment depends on the underlying cause 
6.
Our patient had a typical clinical and radiological pre-
sentation of PAP. It was a second case of this extremely rare
disease in the past 30 years in our clinic.
The results of imaging methods and PFTs  supported
the diagnosis, which was confirmed by open lung biopsy.
Other causes of PAP were not found, and we estimated the
existence of a primary form of the disease which had a pro-
gressive course, with severe ventilatory changes and manife-
sted partial pulmonary failure.
The surgical procedure additionally impaired the lung
function, so there was a lethal outcome of the disease before
obtaining the  histopathologic confirmation and applying a
specific treatment.
Conclusion
We presented a case of rare clinical entity, primary
pulmonary alveolar proteinosis, with typical clinical features
and clinical and radiological course of the disease, in order to
improve a differential diagnostic approach to patients with
bilateral lung infiltrations. In patients with pulmonary alve-
olar proteinosis, the timely diagnosis and adequate treatment
can  improve a prognosis.
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